Pharmena S.A.

Wholesale of perfume and cosmetics

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2008-04-17
Share capital
1,113,775.80 PLN
Activity description

Pharmena is a life science company that develops innovative products and technologies based on the biological potential of 1-MNA, a naturally occurring molecule. Its work combines research, technology development and commercialization, with projects spanning healthy ageing, topical technologies and bioscience focused on 1-MNA.

Registered address
ul. Gdańska 47/49, 90-729 Łódź, Poland
Email
Phone
Social media
Electronic delivery address
AE:PL-92992-28910-DHGBI-16

Financials

Revenue history (in k)

Filing timeliness

Financial statements were filed on time, on average 38 days early. All were audited by a statutory auditor.

  • 202501/07/2026
  • 202401/07/2025
  • 202315/04/2024
  • 202226/06/2023
  • 202105/07/2022
  • 202029/07/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Stock quotes

PLN 2.78
+0.04 (+1.46%)
2.722.742.762.782.7810:0012:0014:0016:00
Open
PLN 2.78
High
PLN 2.78
Low
PLN 2.72
Volume
787
Avg. vol.
1.79K
Market cap
PLN 30.96M
P/E ratio
–
EPS
-PLN 0.27
Shares outstanding
11.14M
52-week
PLN 2.70 – 2.91
Dividend yield
–
Dividend
–
Ex dividend date
–
Exchange
GPW Main Market

Quarterly results

PeriodRevenueEBITNet profit
Q2 2026USD 65.37kUSD -283.63kUSD -269.04k
Q1 2026USD 113.72kUSD -149.11kUSD -129.93k
Q4 2025USD 98.19kUSD -236.82kUSD -223.51k
Q3 2025USD 102.21kUSD -197.64kUSD -173.28k

Results for Q3 2026:Nov 27, 2026

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 50%
Division · Wholesale trade11,738 / 20,054
Top 59%
City · Łódź2,885 / 8,056
Top 36%
Voivodeship · Łódzkie6,262 / 15,329
Top 41%
Country · Poland119,163 / 297,266
Top 40%

Results vs industry

Revenue
This companyUSD 541.44kMedianUSD 334.31kAverageUSD 5.20m
Net profit
This companyUSD -695.38kMedianUSD 5.42kAverageUSD 319.88k
Operating costs
This companyUSD 1.22mMedianUSD 313.53kAverageUSD 4.73m
Assets
This companyUSD 2.74mMedianUSD 189.27kAverageUSD 2.63m

Offer

  • Healthy ageing products
  • Topical technologies
  • Bioscience products
  • 1-MNA research
  • Technology development
  • Product commercialization

Websites

The sites are available in: Polish and English.

  • pharmena.euPharmena SA
    WordPress 7.1ElementorGoogle AnalyticsGoogle Tag ManagerApache
  • endotelio.euEndotelio – molekuła przyszłości
    WooCommerce 10.4WordPress 6.9ElementorGoogle AnalyticsGoogle Tag ManagerPolylangApache

Trademarks

The company holds 6 active trademarks registered with the Polish Patent Office. 7 marks have expired or were not registered. The first mark was filed in 2008.

MarkNumberClassesStatusProtected until
1-MNA Z.4873545Protected Jun 20, 2028
VETOEMVIT Z.4800503, 5, 31Protected Dec 12, 2027
pharmena Z.4534263, 5, 42Protected Mar 11, 2036
MENAREVIN (word)Z.4312845Protected Jul 18, 2034
MENAVITIN (word)Z.4312875Protected Jul 18, 2034
MarkProtected until
1-MNA Jun 20, 2028
VETOEMVIT Dec 12, 2027
pharmena Mar 11, 2036
MENAREVIN (word)Jul 18, 2034
MENAVITIN (word)Jul 18, 2034

Authorized Representatives

Hygin Dariusz Rymdejko age 64 – Attorney-in-fact (sole)
Marzena Ewa Wieczorkowska age 52 – Vice President of the Management Board
Konrad Palka age 56 – President of the Management Board

Manner of representation

Joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations and sign on behalf of the company.

Supervisory board

Agnieszka Danuta Dziki age 45 – Supervisory Board Member
Anna Paczkowska age 47 – Supervisory Board Member
Jacek Dauenhauer age 59 – Supervisory Board Member
Tomasz Michał Filipiak age 63 – Supervisory Board Member
Zbigniew Jacek Molenda age 63 – Supervisory Board Member

Beneficial owners

Pharmena is a public company listed on the Warsaw Stock Exchange, so it does not report beneficial owners to the CRBR (Art. 58 of the Polish AML Act). Its shareholders are disclosed in stock-exchange reports.

Capital group

The company belongs to the Pelion (Poland) group, which is its direct owner. The group has 10 companies, 1 of them abroad.

NameOwnership
61.43%
Menavitin GmbH w likwidacji
13%
73%

Bank accounts

Registered as a VAT taxpayer on 2002-12-30.

  • mBank
    90 1140 0039 0000 4091 7300 2004
  • mBank
    74 1140 0039 0000 4091 7300 2001
  • mBank
    20 1140 0039 0000 4091 7300 2003

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

Publication dateEvent
Sep 11, 2012Commercial Companies Code notice
Aug 29, 2012Commercial Companies Code notice
May 31, 2010Shareholders' meeting convened
May 10, 2010Shareholders' meeting convened

Public aid

6 public aid cases recorded, with a total value of $296,872.

PurposeGross amount
Other crisis aid
$76,971
Other crisis aid
$190.1K
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$10,398

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Śląski Park Technologii Medycznych Kardio-Med Silesia sp. z o.o.
Nanogroup S.A.
Human Biome S.A.
Uvera S.A.
Forvite P.S.A.
Vaxican sp. z o.o.
Protexture sp. z o.o.
Medicofarma Biotech S.A.
Nanosanguis S.A.
Nexbio sp. z o.o.

Change history

DateEvent
2023-09-05Address change
2021-03-08Share capital increase
2019-06-12Share capital increase
2015-07-24PKD change
2013-07-25Share capital increase

FAQ

Last updated: 2026-07-04